Procept Biorobotics stock hits 52-week low at 33.96 USD

Procept Biorobotics Corp’s stock reached a 52-week low, touching 33.96 USD. According to InvestingPro data, the company maintains strong financial health with a current ratio of 9.21, indicating robust liquidity position. This milestone reflects a significant downturn for the company, as its stock has experienced a drastic 1-year change of -53.63%. Despite the decline, the medical device company, known for its innovative robotic systems, has demonstrated impressive revenue growth of 55.71% over the last twelve months. Analysts maintain optimism, with price targets ranging from $51 to $85. Investors are closely monitoring the situation to see if Procept Biorobotics can reverse this trend and regain investor confidence. For deeper insights into PRCT’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 7 additional key ProTips for informed decision-making.

In other recent news, Procept BioRobotics reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.35, compared to the forecasted -$0.41. The company’s revenue also exceeded projections, reaching $79.2 million against a forecast of $76.12 million. Despite these positive results, there were notable developments regarding analyst ratings and projections. Oppenheimer upgraded Procept BioRobotics from Perform to Outperform, citing an attractive risk-reward profile for long-term growth investors. The firm set a price target of $60.00 following a recent meeting with the company. Meanwhile, Wells Fargo adjusted its price target for the company from $75.00 to $58.00, maintaining an Overweight rating. This adjustment followed management’s announcement that no system replacements are expected in the second half of 2025, revising prior expectations of approximately 10 replacements this year. These developments offer a comprehensive view of Procept BioRobotics’ recent performance and analyst perspectives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.